ALDH2 Gene: The Genetic Science Behind Alcohol Metabolism and Sensitivity

You've likely noticed that some people turn red, feel nauseous, or develop a headache after just one or two drinks, while others seem completely unaffected. This isn't just about tolerance built through experience. For a significant proportion of people, particularly those of East Asian descent, it's determined by a genetic variant in the ALDH2 gene that makes alcohol metabolism fundamentally different.

Understanding your ALDH2 genotype, and its companion gene ADH1B, can explain years of puzzling reactions, inform important decisions about alcohol consumption, and carry significant implications for long-term health.

The Two-Step Process of Alcohol Metabolism

When you consume alcohol (ethanol), your body metabolises it through two primary enzymatic steps:

Step 1: Ethanol → Acetaldehyde

The enzyme alcohol dehydrogenase (ADH), encoded primarily by the ADH1B gene, converts ethanol into acetaldehyde. This is a highly toxic intermediate compound, a classified human carcinogen. The speed of this first step is determined largely by your ADH1B genotype.

Step 2: Acetaldehyde → Acetate

The enzyme aldehyde dehydrogenase 2 (ALDH2) converts acetaldehyde into relatively harmless acetate, which is then further metabolised to carbon dioxide and water. The efficiency, or failure, of this second step is the crux of alcohol metabolism genetics.

ALDH2: The Key Gene

ALDH2*1 (Normal Function)

The standard, functional variant of ALDH2 efficiently clears acetaldehyde from the body. Individuals with two copies of ALDH2*1 experience normal alcohol metabolism, acetaldehyde is rapidly converted before it accumulates to toxic levels.

ALDH2*2 (rs671), The "Alcohol Flush" Variant

A single nucleotide change (Glu487Lys) causes a glutamic acid-to-lysine substitution that renders the ALDH2 enzyme 85-95% inactive in heterozygotes and completely inactive in homozygotes. When ALDH2*2 carriers drink alcohol, acetaldehyde accumulates rapidly in the blood, reaching concentrations 5-10 times higher than in non-carriers.

• ALDH2*1/*1 (normal): Efficient acetaldehyde clearance, typical alcohol response
• ALDH2*1/*2 (heterozygous): Approximately 85% reduction in ALDH2 activity. The "flush reaction" occurs, facial flushing, tachycardia, nausea, headache, sometimes hypotension
• ALDH2*2/*2 (homozygous): Complete loss of ALDH2 activity. Even small amounts of alcohol cause severe symptoms. Many homozygous carriers are effectively alcohol-intolerant

The ALDH2*2 variant is extraordinarily common in East Asian populations, affecting approximately 30-50% of people of Chinese, Japanese, Korean, and Vietnamese descent. It is rare in European populations (under 1%) but is the most significant pharmacogenomic variant for alcohol metabolism globally.

The Alcohol Flush Reaction: What's Actually Happening

The characteristic symptoms of the flush reaction, facial redness, increased heart rate, headache, nausea, are direct consequences of acetaldehyde toxicity and the body's vascular response to it:

• Facial flushing: Acetaldehyde causes vasodilation, particularly in skin vasculature
• Increased heart rate: Compensatory cardiovascular response to the drop in blood pressure from vasodilation
• Nausea and vomiting: Direct gastrointestinal toxic effects of acetaldehyde
• Headache: Combination of vasodilation, dehydration, and acetaldehyde neurotoxicity
• Nasal congestion: Histamine release triggered by acetaldehyde

Some individuals use antihistamines (like ranitidine/famotidine) to suppress the visible flushing. This is dangerous: it masks the symptoms while allowing acetaldehyde accumulation to continue unchecked.

The Cancer Risk: A Critically Important Warning

The most significant health implication of ALDH2*2 is not the discomfort of flushing, it is a substantially elevated cancer risk. Acetaldehyde is classified as a Group 1 Human Carcinogen by the International Agency for Research on Cancer (IARC).

When ALDH2*2 carriers continue to drink alcohol, they expose their tissues, particularly the upper aerodigestive tract, to chronically elevated acetaldehyde concentrations. The research findings are stark:

• Oesophageal cancer: ALDH2*1/*2 heterozygotes who drink have approximately 6-10 times higher risk of oesophageal squamous cell carcinoma compared to non-drinkers with normal ALDH2. Homozygous ALDH2*2/*2 heavy drinkers face even higher risk.
• Head and neck cancers: Pharynx, larynx, and oral cavity cancers are significantly elevated
• Liver cancer: Hepatocellular carcinoma risk is elevated in ALDH2*2 carriers who drink
• Stomach cancer: Emerging evidence suggests gastric cancer risk elevation

This risk is compounded when ALDH2*2 is combined with the fast-acting ADH1B*2 variant (common in East Asian populations): rapid ethanol conversion to acetaldehyde combined with impaired acetaldehyde clearance creates maximum acetaldehyde exposure.

ADH1B: The Speed of the First Step

The ADH1B gene encodes the primary alcohol dehydrogenase enzyme. Key variants:

ADH1B*1 (Slow Metaboliser)

Common in European populations. Converts ethanol to acetaldehyde slowly. Individuals may feel the intoxicating effects of ethanol more strongly before acetaldehyde rises, potentially making them more susceptible to the rewarding aspects of alcohol and carrying different addiction risk profiles.

ADH1B*2 (Fast Metaboliser)

Common in East Asian populations. Rapidly converts ethanol to acetaldehyde. When combined with functional ALDH2*1, this creates a fast first step with efficient second step, relatively brisk and clean alcohol metabolism. When combined with ALDH2*2, however, it creates a worst-case scenario: fast acetaldehyde production combined with impaired clearance.

Practical Implications for ALDH2*2 Carriers

The Only Safe Approach

The evidence on cancer risk is sufficiently strong that the scientifically supported recommendation for ALDH2*2 homozygotes is complete avoidance of alcohol. For heterozygotes, the cancer risk scales with consumption, any reduction meaningfully reduces risk.

The flush reaction is not something to be "powered through" or suppressed with medication. It is a biological warning sign, your body's indication that acetaldehyde is accumulating at harmful levels.

Beyond Alcohol: ALDH2 and Nitroglycerin

ALDH2 also metabolises nitroglycerin, the medication used for angina. ALDH2*2 homozygotes have dramatically impaired response to nitroglycerin, which may be life-threatening in cardiac emergencies. This is a critical consideration to discuss with a cardiologist for any ALDH2*2/*2 individual.

Nutritional Considerations for ALDH2*2 Carriers

If some alcohol is consumed, supporting the body's overall detoxification capacity may help mitigate, though cannot eliminate, acetaldehyde toxicity:

• Cruciferous vegetables: Broccoli, cauliflower, and Brussels sprouts support aldehyde detoxification via sulforaphane-induced pathways
• Antioxidant-rich foods: Berries, green tea, and polyphenol-rich vegetables help combat oxidative stress from acetaldehyde
• N-acetylcysteine (NAC): A glutathione precursor that may modestly reduce oxidative stress from acetaldehyde, though evidence is limited
• Adequate hydration: Supports renal acetaldehyde clearance

ALDH2 Research Beyond Alcohol

ALDH2 metabolises multiple aldehydes beyond acetaldehyde, including toxic lipid peroxidation products (like 4-HNE) that accumulate in ischaemic tissue. Research is exploring ALDH2 activation as a therapeutic strategy for myocardial ischaemia-reperfusion injury, neurodegenerative diseases, and diabetes complications, a reminder that this gene has broad biological roles beyond alcohol metabolism.

Key Takeaways

• ALDH2*2 reduces the enzyme's ability to clear acetaldehyde by 85-95%, causing toxic accumulation after alcohol consumption
• The alcohol flush reaction is a symptom of acetaldehyde toxicity, not a harmless cosmetic phenomenon
• ALDH2*2 carriers who drink face significantly elevated risks for oesophageal, head and neck, and liver cancers
• Suppressing flushing symptoms with antihistamines is dangerous, it masks the warning sign while acetaldehyde continues to accumulate
• The only evidence-based risk reduction for ALDH2*2/*2 homozygotes is complete alcohol avoidance; heterozygotes should minimise consumption

Scientific References

Key references include Brooks et al. (2009) on ALDH2 and cancer risk in the International Journal of Cancer, Yokoyama et al. (1998) on oesophageal cancer risk, and the IARC Working Group Reports on acetaldehyde as a carcinogen. The landmark work of Bert Vallee on ADH genetics and drinking behaviour patterns is foundational to this field.